Anabella Villalobos
Vermögen: 45 600 $ am 31.08.2026
Vermögen: 45 600 $ am 31.08.2026
Dr. Anabella Villalobos is an Independent Director at Coya Therapeutics, Inc. She is on the Board of Directors at Coya Therapeutics, Inc. Dr. Villalobos was previously employed as a SVP-Biotherapeutics & Medicinal Sciences by Biogen, Inc. and a Vice President by Pfizer Inc. She received her undergraduate degree from the University of Panama and a doctorate degree from the University of Kansas.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.05.2026 | 10’000 ( 0.04% ) | 45 600 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| COYA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 25.05.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2025 |
| PFIZER INC. | Corporate Officer/Principal | 01.01.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Kansas
University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Panama
University of Panama Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen